RecruitingNot ApplicableNCT06487832

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity

Sponsor

University Hospital Tuebingen

Enrollment

60 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Insulin Resistance Overweight and Obesity Insulin Sensitivity Normal Weight

Summary

The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Subcutaneous GLP1-RA and Subcutaneous placebo for people with insulin resistance, insulin sensitivity, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.